United States Opioid-Induced Constipation Treatment Market to Hit USD 550.5 Million by 2033, Driven by Rising Opioid Usage and Increasing Demand for Targeted Gastrointestinal Therapies

The Global Opioid Induced Constipation Treatment Market reached US$ 1,241.90 million in 2025 and is expected to reach US$ 1,835.00 million by 2033, growing at a CAGR of 5.0% during the forecast period 2026-2033. Growth is driven by increasing use of opioid medications for pain management worldwide. Rising prevalence of chronic pain conditions and associated side effects is boosting demand for effective treatments. Growing awareness among patients and healthcare providers about opioid-induced constipation is further supporting market expansion. Additionally, advancements in targeted therapies and drug formulations are improving treatment outcomes. Expanding healthcare access and supportive regulatory approvals are also contributing to steady market growth.

Download PDF Sample Report:
https://www.datamintelligence.com/download-sample/opioid-induced-constipation-treatment-market?prasad

Opioid Induced Constipation Treatment Market Major Players:

AstraZeneca

AstraZeneca is a leading global biopharmaceutical company with strong capabilities in gastrointestinal and specialty care therapeutics. In 2025, AstraZeneca reported revenue of USD 52.0 billion, driven by its oncology, cardiovascular, and rare disease portfolios. In the opioid-induced constipation (OIC) treatment market, AstraZeneca plays a key role through its development and commercialization of gastrointestinal therapies that address opioid-related side effects. Its strong R&D pipeline and global commercial presence enable it to support improved patient outcomes in pain management and supportive care.

Shionogi & Company, Limited

Shionogi is a prominent pharmaceutical company with expertise in pain management and gastrointestinal therapies. In 2025, the company reported revenue of USD 3.0 billion, supported by its focus on infectious diseases and specialty pharmaceuticals. In the opioid-induced constipation treatment market, Shionogi plays a major role through its development of targeted therapies designed to counteract opioid-related bowel dysfunction. Its innovative drug portfolio and research focus position it as an important contributor to improving quality of life for patients undergoing opioid treatment.

Takeda Pharmaceuticals Company Ltd

Takeda Pharmaceuticals is one of the largest global pharmaceutical companies, with strong expertise in gastrointestinal and specialty care treatments. In 2025, Takeda reported revenue of USD 30.0 billion, driven by its core therapeutic areas including gastroenterology, rare diseases, and neuroscience. In the opioid-induced constipation treatment market, Takeda plays a significant role through its development of advanced therapies that target opioid receptor pathways in the gastrointestinal tract. Its strong global presence and innovation in GI treatments make it a key player in addressing opioid-related side effects and improving patient care outcomes.

Find the Right Partner to Accelerate Your Growth Today with Our Latest Report:
https://www.datamintelligence.com/partner-identification-enquiry/opioid-induced-constipation-treatment-market?prasad

United States: Recent Industry Developments

✅ In March 2026, Bausch Health Companies expanded therapies for opioid-induced constipation with improved formulations. The innovation enhances patient comfort. Bausch continues advancing gastrointestinal treatments.

✅ In February 2026, AstraZeneca enhanced pipeline drugs targeting opioid-related gastrointestinal disorders. The development improves treatment efficacy. AstraZeneca continues strengthening GI portfolio.

✅ In January 2026, Ironwood Pharmaceuticals expanded therapies for chronic constipation including opioid-induced conditions. The initiative improves patient outcomes. Ironwood continues advancing GI innovation.

✅ In December 2025, Pfizer Inc. enhanced research on treatments for opioid-induced side effects. The development supports patient care. Pfizer continues strengthening pharma pipeline.

Japan: Recent Industry Developments

✅ In March 2026, Shionogi & Co., Ltd. expanded treatments targeting opioid-induced constipation. The innovation improves patient management. Shionogi continues advancing GI therapies.

✅ In February 2026, Takeda Pharmaceutical Company enhanced gastrointestinal drug portfolio including constipation therapies. The development improves outcomes. Takeda continues strengthening pipeline.

✅ In January 2026, Astellas Pharma expanded research on opioid-related treatment solutions. The initiative improves patient care. Astellas continues advancing healthcare innovation.

✅ In December 2025, Daiichi Sankyo enhanced GI treatment research for opioid side effects. The development improves therapy options. Daiichi Sankyo continues strengthening portfolio.

Segment Covered in the Opioid Induced Constipation Treatment Market:

By Drug Class: Mu-Opioid Receptor Antagonists (PAMORAs)
Mu-opioid receptor antagonists (PAMORAs) dominate the opioid-induced constipation (OIC) treatment market as they directly target the underlying mechanism of OIC without affecting central analgesia. Drugs such as Methylnaltrexone, Naloxegol, and Naldemedine are widely prescribed due to their proven efficacy and safety profiles.
PAMORAs account for approximately 62% of the total market. Based on a global market size assumption of USD 3.1 billion in 2025, this translates to an estimated segment value of USD 1.9 billion. Growth is driven by increasing opioid prescriptions, rising awareness of OIC management, and strong clinical adoption of targeted therapies.

By Distribution Channel: Retail Pharmacies
Retail pharmacies dominate the distribution channel segment due to their widespread accessibility and role in dispensing chronic medications. Patients undergoing long-term opioid therapy often rely on retail pharmacies for convenient access to OIC treatments.
This segment accounts for approximately 48% of the total market. Based on the USD 3.1 billion global market size in 2025, this corresponds to an estimated value of USD 1.5 billion. Growth is driven by increasing outpatient treatment, accessibility of medications, and expansion of pharmacy networks.

By Mode of Administration: Oral
Oral administration is the leading segment due to its convenience, patient compliance, and suitability for long-term treatment. Most OIC medications, including PAMORAs and chloride channel activators, are available in oral formulations.
This segment accounts for approximately 67% of the total market. Based on the USD 3.1 billion global market size in 2025, this corresponds to an estimated value of USD 2.1 billion. Growth is driven by patient preference, ease of use, and increasing availability of oral drug formulations.

Market Segmentation

The Opioid-Induced Constipation Treatment Market is segmented by drug class into mu-opioid receptor antagonists (including PAMORAs), chloride channel activators, and others; by distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies; by mode of administration into oral and parenteral; and by region into North America, Latin America, and Europe.

Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/opioid-induced-constipation-treatment-market?prasad

Regional Analysis

North America
North America is the leading market due to high opioid usage, strong healthcare infrastructure, and availability of advanced treatment options. The region is led by the United States.
The North American market is estimated at approximately USD 1.4 billion in 2025, accounting for about 45% of the global market. Growth is driven by high prevalence of chronic pain conditions, increasing awareness of OIC, and strong adoption of prescription therapies.

Europe
Europe is a significant market supported by well-established healthcare systems, increasing awareness of opioid-related side effects, and growing adoption of targeted therapies. Key contributors include Germany, France, and the United Kingdom.
The European market is valued at approximately USD 1.1 billion in 2025, representing about 35% of the global market. Growth is driven by improved diagnosis, regulatory support, and increasing patient awareness.

Data-Driven Research Methodology for the Opioid Induced Constipation Treatment Market:

Our research process for the Opioid Induced Constipation Treatment Market at DataM Intelligence combines rigorous primary and secondary research to ensure accurate and reliable insights. We engage with industry experts, key stakeholders, and validated data sources to capture real-time market dynamics. Advanced analytical tools and proprietary models are applied to forecast trends, competitive landscapes, and growth opportunities. Each report undergoes multi-level validation to deliver actionable intelligence that supports strategic decision-making.

Purchase the Exclusive Report:
https://www.datamintelligence.com/buy-now-page?report=opioid-induced-constipation-treatment-market?prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Contact Us-
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About Us
DataM Intelligence is a market research and consulting firm that delivers comprehensive end-to-end business solutions, covering everything from in-depth research to strategic consulting. The company leverages key industry trends, insights, and developments to provide fast, reliable, and actionable solutions tailored to diverse client requirements.
It offers both syndicated and customized research reports supported by a strong and robust methodology. With an extensive database comprising 9000+ reports across 40+ industry domains, DataM Intelligence serves over 200 companies in more than 50 countries, helping organizations access critical business intelligence that drives informed decision-making and sustainable growth.

This release was published on openPR.